Gosset Ownership
Private
Therapeutic Areas
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Dynogen Pharmaceuticals General Information
Dynogen developed small molecule therapies for gastrointestinal and genitourinary disorders. Its lead programs included DDP200 for overactive bladder, DDP225 for IBS-d and chronic functional vomiting, and DDP733 for IBS-c and n-GERD. The company advanced several candidates into clinical trials but was unable to secure further financing after disappointing clinical data in one program. It entered administration in February 2009.
Contact Information
Primary Industry
Biotech
Corporate Office
Cambridge/Boston area, Massachusetts/North Carolina
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
None documented; a merger agreement with Apex Bioventures was announced but not completed due to market conditions.
Dynogen Pharmaceuticals Funding
No funding data available
To view Dynogen Pharmaceuticals's complete valuation and funding history, request access »